Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
This week in Oncology
Oncology — Sep 7 – Sep 11, 2026 (Wk 37): Oncology Theme: Earnings, Analyst Targets, and Pipeline Updates Drive Activity →This week in oncology saw a mix of company-specific news, including earnings reports and analyst target adjustments, alongside updates on drug pipelines. These developments highlight the ongoing focus on clinical progress and financial performance within the…
BOLD
Valuation N/A
Boundless Bio, Inc.
Price$2.81
Model IV—
P/IV—
Limited data — see page
BOLT
Deeply undervalued
Bolt Biotherapeutics, Inc.
Price$3.95
Model IV$28.19
P/IV0.19
Discount 86%
Return to IV: +613.7%
Market implies -42.8%/yr
vs model +50.0% · below model
BRNS
Valuation N/A
Barinthus Biotherapeutics plc.
Price$0.74
Model IV—
P/IV—
Market implies +5.3%/yr
vs model +15.0% · below model
BTAI
Valuation N/A
BioXcel Therapeutics, Inc.
Price$0.05
Model IV—
P/IV—
Market implies +12.5%/yr
vs model +15.0% · in line
BYSI
Valuation N/A
BeyondSpring Inc.
Price$0.76
Model IV—
P/IV—
Market implies +30.5%/yr
vs model +15.0% · above model
CAI
Deeply undervalued
Caris Life Sciences, Inc.
Price$24.34
Model IV$37.69
P/IV0.44
Discount 35%
Return to IV: +54.8%
Market implies -5.8%/yr
vs model +50.0% · below model
CANF
Valuation N/A
Can-Fite BioPharma Ltd.
Price$2.33
Model IV—
P/IV—
Market implies +30.1%/yr
vs model +2.0% · above model
CATX
Valuation N/A
Perspective Therapeutics, Inc.
Price$2.81
Model IV—
P/IV—
Market implies +68.0%/yr
vs model +15.0% · above model
CCCC
Valuation N/A
C4 Therapeutics, Inc.
Price$3.51
Model IV—
P/IV—
Market implies +67.0%/yr
vs model +2.0% · above model
CELC
Valuation N/A
Celcuity Inc.
Price$83.45
Model IV—
P/IV—
Limited data — see page
CELU
Deeply overvalued
Celularity Inc
Price$1.41
Model IV$0.63
P/IV1.60
Premium +124%
Return to IV: -55.3%
Market implies +6.3%/yr
vs model +5.6% · in line
CGEM
Valuation N/A
Cullinan Therapeutics, Inc.
Price$20.59
Model IV—
P/IV—
Market implies +58.0%/yr
vs model +15.0% · above model
CGEN
Deeply undervalued
COMPUGEN LTD
Price$2.47
Model IV$8.67
P/IV0.30
Discount 72%
Return to IV: +251.0%
Market implies -1.7%/yr
vs model +25.0% · below model
CHRS
Valuation N/A
Coherus Oncology, Inc.
Price$1.33
Model IV—
P/IV—
Market implies +57.0%/yr
vs model +2.0% · above model
CLDI
Valuation N/A
Calidi Biotherapeutics, Inc.
Price$1.17
Model IV—
P/IV—
Limited data — see page
CLDX
Valuation N/A
Celldex Therapeutics, Inc.
Price$39.18
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +2.0% · above model
CLLS
Valuation N/A
Cellectis S.A.
Price$3.10
Model IV—
P/IV—
Limited data — see page
CLRB
Valuation N/A
Cellectar Biosciences, Inc.
Price$2.31
Model IV—
P/IV—
Limited data — see page
CMPX
Valuation N/A
Compass Therapeutics, Inc.
Price$2.00
Model IV—
P/IV—
Market implies +82.9%/yr
vs model +15.0% · above model
CNSP
Valuation N/A
CNS Pharmaceuticals, Inc.
Price$5.84
Model IV—
P/IV—
Limited data — see page
CNTA
Valuation N/A
Centessa Pharmaceuticals plc
Price$40.50
Model IV—
P/IV—
Market implies +83.7%/yr
vs model +15.0% · above model
CNTB
Valuation N/A
Connect Biopharma Holdings Ltd
Price$2.04
Model IV—
P/IV—
Market implies +63.9%/yr
vs model +15.0% · above model
CNTX
Valuation N/A
Context Therapeutics Inc.
Price$0.35
Model IV—
P/IV—
Limited data — see page
COGT
Valuation N/A
Cogent Biosciences, Inc.
Price$33.41
Model IV—
P/IV—
Limited data — see page
CORT
Valuation N/A
CORCEPT THERAPEUTICS INC
Price$112.79
Model IV—
P/IV—
Market implies +32.2%/yr
vs model +20.1% · above model
CRBP
Valuation N/A
Corbus Pharmaceuticals Holdings, Inc.
Price$6.92
Model IV—
P/IV—
Market implies +58.1%/yr
vs model +15.0% · above model
CRBU
Valuation N/A
Caribou Biosciences, Inc.
Price$1.27
Model IV—
P/IV—
Market implies +64.6%/yr
vs model +3.8% · above model
CRDF
Valuation N/A
Cardiff Oncology, Inc.
Price$1.21
Model IV—
P/IV—
Market implies +77.6%/yr
vs model +13.4% · above model
CRIS
Valuation N/A
CURIS INC
Price$1.13
Model IV—
P/IV—
Market implies +28.7%/yr
vs model +2.0% · above model
CRMD
Valuation N/A
CorMedix Inc.
Price$7.83
Model IV—
P/IV—
Limited data — see page
CRSP
Valuation N/A
CRISPR Therapeutics AG
Price$51.72
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +2.0% · above model
CRVS
Valuation N/A
Corvus Pharmaceuticals, Inc.
Price$12.91
Model IV—
P/IV—
Limited data — see page
CSBR
Deeply undervalued
CHAMPIONS ONCOLOGY, INC.
Price$5.10
Model IV$11.38
P/IV0.51
Discount 55%
Return to IV: +123.2%
Market implies -4.6%/yr
vs model +9.5% · below model
CSTL
Deeply undervalued
CASTLE BIOSCIENCES INC
Price$32.33
Model IV$70.42
P/IV0.07
Discount 54%
Return to IV: +117.8%
Market implies -17.0%/yr
vs model +38.3% · below model
CTMX
Valuation N/A
CytomX Therapeutics, Inc.
Price$3.29
Model IV—
P/IV—
Market implies +21.4%/yr
vs model +19.5% · in line
CTOR
Valuation N/A
CITIUS ONCOLOGY, INC.
Price$0.94
Model IV—
P/IV—
Limited data — see page
CTXR
Valuation N/A
Citius Pharmaceuticals, Inc.
Price$0.58
Model IV—
P/IV—
Market implies +67.7%/yr
vs model +15.0% · above model
CUE
Valuation N/A
Cue Biopharma, Inc.
Price$30.55
Model IV—
P/IV—
Market implies +92.7%/yr
vs model +16.4% · above model
CVM
Valuation N/A
CEL SCI CORP
Price$1.49
Model IV—
P/IV—
Limited data — see page
CYDY
Valuation N/A
CytoDyn Inc.
Price$0.20
Model IV—
P/IV—
Market implies +93.8%/yr
vs model +15.0% · above model
DCTH
Fairly valued
DELCATH SYSTEMS, INC.
Price$15.91
Model IV$12.42
P/IV0.87
Premium +28%
Return to IV: -21.9%
Market implies +5.0%/yr
vs model +50.0% · below model
DRTS
Valuation N/A
Alpha Tau Medical Ltd.
Price$14.43
Model IV—
P/IV—
Limited data — see page
DRTSW
Valuation N/A
Alpha Tau Medical Ltd.
Price$3.84
Model IV—
P/IV—
Limited data — see page
DTIL
Valuation N/A
PRECISION BIOSCIENCES INC
Price$7.17
Model IV—
P/IV—
Market implies +24.1%/yr
vs model +2.0% · above model
EDAP
Overvalued
EDAP TMS SA
Price$5.43
Model IV$3.55
P/IV1.22
Premium +53%
Return to IV: -34.6%
Market implies -0.8%/yr
vs model +15.0% · below model
ELTX
Valuation N/A
Elicio Therapeutics, Inc.
Price$1.99
Model IV—
P/IV—
Market implies +34.0%/yr
vs model +15.0% · above model
ELVN
Valuation N/A
Enliven Therapeutics, Inc.
Price$54.32
Model IV—
P/IV—
Limited data — see page
ENGN
Valuation N/A
enGene Therapeutics Inc.
Price$1.80
Model IV—
P/IV—
Limited data — see page
ENVB
Valuation N/A
Enveric Biosciences, Inc.
Price$1.42
Model IV—
P/IV—
Limited data — see page
ERAS
Valuation N/A
Erasca, Inc.
Price$16.16
Model IV—
P/IV—
Limited data — see page
ESLA
Valuation N/A
Estrella Immunopharma, Inc.
Price$0.66
Model IV—
P/IV—
Limited data — see page
EVAX
Valuation N/A
Evaxion A/S
Price$3.13
Model IV—
P/IV—
Limited data — see page
EXEL
Deeply undervalued
EXELIXIS, INC.
Price$56.12
Model IV$88.60
P/IV0.57
Discount 37%
Return to IV: +57.9%
Market implies +5.7%/yr
vs model +15.2% · below model
FATE
Valuation N/A
FATE THERAPEUTICS INC
Price$2.31
Model IV—
P/IV—
Market implies +92.2%/yr
vs model +2.0% · above model
FBIO
Deeply overvalued
Fortress Biotech, Inc.
Price$2.52
Model IV$1.22
P/IV2.30
Premium +107%
Return to IV: -51.8%
Market implies +6.0%/yr
vs model +2.0% · above model
FENC
Valuation N/A
FENNEC PHARMACEUTICALS INC.
Price$10.64
Model IV—
P/IV—
Market implies +32.2%/yr
vs model +15.0% · above model
FHTX
Deeply overvalued
Foghorn Therapeutics Inc.
Price$4.36
Model IV$1.32
P/IV3.25
Premium +231%
Return to IV: -69.8%
Market implies +21.7%/yr
vs model +50.0% · below model
GALT
Valuation N/A
GALECTIN THERAPEUTICS INC
Price$3.91
Model IV—
P/IV—
Limited data — see page
GANX
Valuation N/A
Gain Therapeutics, Inc.
Price$1.75
Model IV—
P/IV—
Market implies +109.2%/yr
vs model +15.0% · above model
GDTC
Valuation N/A
CytoMed Therapeutics Ltd
Price$0.78
Model IV—
P/IV—
Limited data — see page